麦斯莫医疗 2025年季度报告

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 MASIMO CORPORATION (Exact Name of Registrant as Specified in its Charter)________________________________________________ Delaware(State or Other Jurisdiction ofIncorporation or Organization)52 DiscoveryIrvine,California 33-0368882(I.R.S. EmployerIdentification Number)92618(Zip Code) (949)297-7000 (Registrant’s Telephone Number, Including Area Code) Securities Registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or15(d) of the Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period thatthe registrant was required to file such reports), and (2)has been subject to such filing requirements for thepast 90days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File requiredto be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large acceleratedfiler Acceleratedfiler☐Smallerreportingcompany☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the ExchangeAct.) Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: Commonstock,$0.001parvalue PARTI. Financial Information Item1.Financial Statements (unaudited):Condensed Consolidated Balance Sheets as of March 29, 2025 and December 28, 2024Condensed Consolidated Statements of Operations for the three months ended March 29, 2025 andMarch 30, 2024 Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 29, 2025 and March 30, 2024 PARTII. Other Information Item1.Legal ProceedingsItem1A.Risk FactorsItem 5.Other InformationItem6.ExhibitsSignatures PART I. FINANCIAL INFORMATION MASIMO CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Net cash provided by (used in) financing activities 1. Description of the Company Masimo Corporation (the “Company”) is a global technology company that develops, manufactures and markets a wide array ofpatient monitoring technologies, as well as automation and connectivity solutions. The Company’s mission is to improve patientoutcomes, reduce the cost of care and take noninvasive monitoring to new sites and applications. As of March 29, 2025, the Company The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietarysingle-patient use or reusable sensors, software and/or cables. The Company primarily sells its healthcare products to hospitals,emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers The Company’s non-healthcare consumer business incorporates audio and home integration technologies are primarily sold or licenseddirect-to-consumers, or through authorized retailers and wholesalers. As of December 28, 2024, the non-healthcare consumer business remained part of the Company’s continuing operations.Subsequently, the sales process has progressed in early 2025, and as of March 29, 2025, the non-healthcare consumer business hasbeen classified as held-for-sale, and reported as discontinued operations. For additional information with respect to the non-healthcareconsumer business separation and discontinued operations of this business, please see Note 18, “Discontinued Operations”. On May 6, The terms “the Company” and “Masimo” refer to Masimo Corporation and, where applicable, its consolidated subsidiaries. 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations ofthe Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statementsprepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensedor omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have be